Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Iannuzzo, Gabriella
PREVAIL, NCT05202509 / 2021-005092-39: Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease	Active, not recruiting	3	9541	Europe, Canada, Japan, US, RoW	Obicetrapib, Placebo	NewAmsterdam Pharma, Monash University	Atherosclerotic Cardiovascular Disease	11/26	11/26
AT-TARGET-IT, NCT05430828: Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in Italy	Recruiting	N/A	2000	Europe	Repatha (evolocumab); Praluent (alirocumab)	Federico II University	Hypercholesterolemia	03/24	03/24
NCT02135705: LOWER: Lomitapide Observational Worldwide Evaluation Registry 1-year data from LOWER registry in HoFH at NLA 2016 May 2016 - May 2016: 1-year data from LOWER registry in HoFH at NLA 2016	Recruiting	N/A	300	Europe, Canada, US, RoW	Lomitapide, Juxtapid, Lojuxta	Amryt Pharma	Homozygous Familial Hypercholesterolemia	03/28	09/28